- Previous Close
0.0170 - Open
0.0170 - Bid 0.0150 x --
- Ask 0.0160 x --
- Day's Range
0.0150 - 0.0170 - 52 Week Range
0.0150 - 0.1100 - Volume
3,549,849 - Avg. Volume
545,326 - Market Cap (intraday)
13.536M - Beta (5Y Monthly) -0.64
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 25, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.
www.biotron.com.auRecent News: BIT.AX
View MorePerformance Overview: BIT.AX
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIT.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIT.AX
View MoreValuation Measures
Market Cap
13.54M
Enterprise Value
13.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.21
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-208.89%
Return on Assets (ttm)
-94.68%
Return on Equity (ttm)
-234.68%
Revenue (ttm)
1.65M
Net Income Avi to Common (ttm)
-3.44M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
393.2k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.33M